Margaret A.WinkerMD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Senior EditorIndividualAuthor
To the Editor.—The study by Dr Burge
and colleagues1 was designed to compare
blood glucose levels following a prolonged fast among older persons exposed
to glyburide and glipizide. The study is justifiable because glipizide, manufactured
by the study sponsor, may stimulate less insulin secretion in the fasting
state and may, therefore, produce less hypoglycemia following a prolonged
fast than does glyburide.2 Also, there is
a 2-fold increase in the risk of serious hypoglycemia among older adults prescribed
glyburide compared with glipizide.3 In this
experimental setting, there were no differences in fasting glucose levels
between glyburide and glipizide and no hypoglycemia occurred among study participants.
Shorr RI. Hypoglycemia From Glipizide and Glyburide. JAMA. 1998;279(18):1441–1443. doi:10-1001/pubs.JAMA-ISSN-0098-7484-279-18-jac80006
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: